HCM
ALXN

Highbridge Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Highbridge Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,300
Closed -$235K – 1908
2015
Q2 		$235K Buy
+1,300
New +$224K ﹤0.01% 1228
2013
Q3 		– Sell
-7,400
Closed -$683K – 1589
2013
Q2 		$683K Buy
+7,400
New +$713K 0.01% 787

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Highbridge Capital Management's ALXN Position: Q4 2018 in Review

Highbridge Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 9,920 shares — an estimated $1.38M sold.

Highbridge Capital Management first reported a position in ALXN in Q2 2013 and held it in 15 quarters. The position peaked at $33.5M in Q1 2015. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Highbridge Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 9,920 Alexion Pharmaceuticals shares in Q4 2018, an estimated $1.38M.
  • Highbridge Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Highbridge Capital Management's Alexion Pharmaceuticals position peaked at $33.5M in Q1 2015.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Highbridge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.